Production (Stage)
MIRA Pharmaceuticals, Inc.
MIRA
$1.40
$0.032.19%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.57% | -32.22% | 22.31% | 87.70% | 44.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.05% | -5.96% | 26.69% | 77.75% | 29.48% |
| Operating Income | 10.05% | 5.96% | -26.69% | -77.75% | -29.48% |
| Income Before Tax | 35.93% | 34.46% | -48.99% | -121.67% | -78.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.93% | 34.46% | -48.99% | -121.67% | -78.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.93% | 34.46% | -48.99% | -121.67% | -78.49% |
| EBIT | 10.05% | 5.96% | -26.69% | -77.75% | -29.48% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 42.01% | 38.06% | -58.65% | -151.48% | -95.90% |
| Normalized Basic EPS | 41.99% | 38.05% | -58.71% | -151.57% | -95.91% |
| EPS Diluted | 43.88% | 33.97% | -65.72% | -161.08% | -103.55% |
| Normalized Diluted EPS | 41.99% | 38.05% | -58.71% | -151.57% | -95.91% |
| Average Basic Shares Outstanding | 11.58% | 2.88% | -21.27% | -22.69% | -24.43% |
| Average Diluted Shares Outstanding | 11.58% | 2.88% | -21.27% | -22.69% | -24.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |